Elanco Animal Health (ELAN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Elanco Animal Health (ELAN) has a cash flow conversion efficiency ratio of 0.016x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($108.00 Million) by net assets ($6.55 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Elanco Animal Health - Cash Flow Conversion Efficiency Trend (2016–2025)
This chart illustrates how Elanco Animal Health's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Elanco Animal Health (ELAN) financial obligations for a breakdown of total debt and financial obligations.
Elanco Animal Health Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Elanco Animal Health ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Huaneng Power International Inc
SHG:600011
|
0.105x |
|
Grupo Aeroportuario del Pacifico SAB De CV ADR
NYSE:PAC
|
0.207x |
|
CITIC Pacific Special Steel Group Co Ltd
SHE:000708
|
0.086x |
|
Fuzhou Rockchip Electronics Co Ltd
SHG:603893
|
0.034x |
|
DIETEREN GR. UNSP.ADR 1/2
F:DJD
|
N/A |
|
BUDWEISER BREW.UNSP.ADR/4
F:4BB1
|
N/A |
|
Gildan Activewear Inc.
TO:GIL
|
0.087x |
|
Zhejiang Zheneng Electric Power Co Ltd
SHG:600023
|
0.074x |
Annual Cash Flow Conversion Efficiency for Elanco Animal Health (2016–2025)
The table below shows the annual cash flow conversion efficiency of Elanco Animal Health from 2016 to 2025. For the full company profile with market capitalisation and key ratios, see Elanco Animal Health (ELAN) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $6.55 Billion | $560.00 Million | 0.086x | -3.62% |
| 2024-12-31 | $6.10 Billion | $541.00 Million | 0.089x | +103.79% |
| 2023-12-31 | $6.22 Billion | $271.00 Million | 0.044x | -29.77% |
| 2022-12-31 | $7.29 Billion | $452.00 Million | 0.062x | -3.61% |
| 2021-12-31 | $7.51 Billion | $483.00 Million | 0.064x | +1429.93% |
| 2020-12-31 | $8.48 Billion | $-41.00 Million | -0.005x | -111.97% |
| 2019-12-31 | $5.55 Billion | $224.10 Million | 0.040x | -56.91% |
| 2018-12-31 | $5.20 Billion | $487.30 Million | 0.094x | +320.28% |
| 2017-12-31 | $7.79 Billion | $173.80 Million | 0.022x | +0.57% |
| 2016-12-31 | $7.03 Billion | $155.90 Million | 0.022x | -- |
About Elanco Animal Health
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals worldwide. The company offers pet health products, such as parasiticides, vaccines, and therapeutics that protect pets from fleas, ticks, and internal parasites under the Seresto, K-9 Advantage, Advantix, and Advocate trademarks; prescription parasiticide … Read more